8-K: TG Therapeutics Q2 2025: Strong BRIUMVI Sales, Raised Guidance

TG Therapeutics reports robust second quarter 2025 financial results, driven by strong BRIUMVI sales, leading to an upward revision of full-year revenue guidance.

Summary

• Total revenue for the second quarter of 2025 was $141.1 million.
• BRIUMVI U.S. net product revenue reached $138.8 million in Q2 2025, representing 91% growth over Q2 2024 and 16% growth over Q1 2025.
• Full year 2025 BRIUMVI U.S. net revenue target has been raised to approximately $570 $575 million, up from the prior guidance of $560 million.
• Total global revenue target for full year 2025 has been raised to approximately $585 million, up from the prior guidance of $575 million.
• Net income for the second quarter of 2025 was $28.2 million, compared to $6.9 million in Q2 2024.
• Net income for the six months ended June 30, 2025, was $33.2 million, a significant improvement from a net loss of $(3.8) million for the same period in 2024.
• Cash, cash equivalents, and investment securities stood at $278.9 million as of June 30, 2025.
• BRIUMVI commercialization has expanded outside the U.S., with approvals in the European Union, United Kingdom, Switzerland, and Australia through partner Neuraxpharm.
• Patient enrollment has commenced for the randomized Phase 3 pivotal program (ENHANCE trial) to evaluate a consolidated Day 1 and Day 15 dosing regimen for IV BRIUMVI.
• The first patient with progressive multiple sclerosis has been dosed in the Phase 1 clinical trial evaluating azer-cel for the treatment of autoimmune diseases.

Sentiment

Score: 8

Explanation: The filing indicates strong commercial performance for BRIUMVI, leading to increased revenue guidance and significant improvements in net income. The company is also advancing its pipeline with new formulations and indications, and states it has sufficient cash to fund operations. The risks mentioned are standard for a biopharmaceutical company and do not overshadow the positive operational and financial updates.

Positives

• Strong BRIUMVI U.S. net product revenue of $138.8 million in Q2 2025, demonstrating 91% growth year-over-year and 16% quarter-over-quarter.
• Raised full-year 2025 BRIUMVI U.S. net revenue guidance to $570 $575 million, indicating robust commercial momentum and confidence.
• Increased full-year 2025 total global revenue target to approximately $585 million.
• Significant improvement in net income, reaching $28.2 million in Q2 2025 compared to $6.9 million in Q2 2024, and achieving positive net income for the first half of 2025.
• Successful expansion of BRIUMVI commercialization into key international markets including the EU, UK, Switzerland, and Australia.
• Advancement of pipeline with the commencement of patient enrollment in the Phase 3 ENHANCE trial for a streamlined IV BRIUMVI dosing regimen and the initiation of a Phase 1 trial for azer-cel in autoimmune diseases.
• The company's cash position of $278.9 million as of June 30, 2025, combined with projected revenues, is anticipated to be sufficient to fund current operating plans.

Negatives

• Research and development (R&D) expenses increased to $31.8 million in Q2 2025 from $17.6 million in Q2 2024, primarily due to subcutaneous ublituximab development work.
• Selling, general and administrative (SG&A) expenses rose to $55.6 million in Q2 2025 from $38.8 million in Q2 2024, mainly due to increased marketing, personnel, and external costs associated with BRIUMVI commercialization.
• License, milestone, royalty, and other revenue for the six months ended June 30, 2025, was lower ($3.5 million) compared to the same period in 2024 ($13.9 million), primarily due to a non-recurring $12.5 million milestone payment received in Q1 2024.

Risks

• The company's ability to continue to commercialize BRIUMVI.
• The risk that trends in prescriptions are not maintained or that prescriptions are not filled.
• The failure to obtain and maintain payor coverage for BRIUMVI.
• The risk that healthcare professional interest in BRIUMVI will not be sustained.
• The risk that momentum in sales for BRIUMVI will not be sustained during the course of the year.
• The risk that BRIUMVI revenue targets will not be achieved.
• The failure to obtain and maintain requisite regulatory approvals, including satisfying post-approval regulatory requirements.
• The potential for variations from the company's projections and estimates about the potential market for BRIUMVI due to factors such as further limitations regulators may impose on required labeling (e.g., from safety signals).
• The company's ability to meet post-approval compliance obligations related to product quality, distribution, supply chain, pharmacovigilance, and sales and marketing.
• Reliance on third parties for manufacturing, distribution, supply, and other support functions for clinical and commercial products.
• The risk that any individual patient's clinical experience or the aggregate patient experience in the post-marketing setting may differ from that demonstrated in controlled clinical trials.
• The risk that the company does not achieve its 2025 development pipeline anticipated milestones or goals in the projected timeframe or at all, including commencing and completing pivotal programs for subcutaneous ublituximab and streamlined IV dosing, and enrolling patients into trials for BRIUMVI in Myasthenia Gravis or azer-cel.
• The risk that the subcutaneous Phase 3 program or the ENHANCE Phase 3 trial will not be successful, approved by the FDA, or achieve commercial acceptance.
• The uncertainties generally inherent in research and development.
• Regulatory developments, legislative actions, executive orders, including the imposition of tariffs and policy changes in the U.S. and other jurisdictions.
• General political, economic, and business conditions.

Future Outlook

The company raised its full-year 2025 BRIUMVI U.S. net revenue target to $570 $575 million and its total global revenue target to approximately $585 million, citing strong commercial momentum and physician confidence. They anticipate their current cash position combined with projected revenues will be sufficient to fund operations. Future pipeline goals include commencing Phase 3 for subcutaneous BRIUMVI, continuing enrollment for streamlined IV dosing in the ENHANCE trial, and continuing enrollment for BRIUMVI in Myasthenia Gravis and azer-cel in autoimmune diseases.

Management Comments

• "We're incredibly proud of the continued momentum behind BRIUMVI, which we believe is establishing itself as a leading anti-CD20 therapy in adults with relapsing MS."
• "The strong uptake we're seeing, combined with deepening physician confidence and compelling patient experiences, underscores the strength of our launch strategy and gives us confidence in reaching our updated 2025 full year BRIUMVI U.S. net revenue guidance of $570 to $575 million."
• "With important innovations like our subcutaneous formulation and combined day one and day fifteen IV dosing currently being studied, we believe BRIUMVI is well positioned to lead the class and redefine treatment expectations for people living with MS."

Industry Context

TG Therapeutics operates in the highly competitive multiple sclerosis (MS) treatment market, specifically with its anti-CD20 monoclonal antibody, BRIUMVI. The strong growth of BRIUMVI and its positioning as a "leading anti-CD20 therapy" suggests it is gaining significant market share against established competitors in the relapsing MS segment. The company's focus on new formulations (subcutaneous) and dosing regimens (consolidated IV) indicates a strategy to enhance patient convenience and potentially expand market reach, aligning with broader industry trends towards more patient-friendly administration methods for chronic conditions. The expansion into autoimmune diseases with azer-cel and BRIUMVI in Myasthenia Gravis also reflects a common biopharmaceutical strategy of leveraging existing platforms for new indications.

Comparison to Industry Standards

• BRIUMVI is positioned as a leading anti-CD20 therapy, a class that includes established drugs like Ocrevus (ocrelizumab) from Roche/Genentech and Kesimpta (ofatumumab) from Novartis. While specific comparative sales figures are not provided in the filing, BRIUMVI's 91% year-over-year growth in Q2 2025 suggests a rapid uptake phase, potentially outpacing the growth rates of more mature anti-CD20 therapies in the MS market.
• The development of a subcutaneous formulation for BRIUMVI aligns with industry trends seen with other MS therapies, such as Kesimpta, which is already a subcutaneous anti-CD20. This development aims to offer patients more convenient at-home administration, a key competitive differentiator.
• The ENHANCE trial for consolidated IV dosing (Day 1 and Day 15) aims to streamline the infusion process, potentially making BRIUMVI more appealing compared to other IV anti-CD20s that may require more frequent or complex initial dosing schedules.
• The expansion into Myasthenia Gravis (MG) and other autoimmune diseases with azer-cel is a common strategy for companies with B-cell targeting therapies, as B-cell dysfunction is implicated in various autoimmune conditions. This mirrors the broader application of drugs like rituximab (Rituxan) or ocrelizumab beyond their initial indications.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, increased guidance, improved profitability, and pipeline advancements, potentially leading to increased share value.
• Patients (MS): Positive impact through continued availability and potential future improvements in administration (subcutaneous, streamlined IV dosing) of BRIUMVI, offering more treatment options.
• Employees: Positive impact from company growth and commercial success, potentially leading to job security and expansion.
• Healthcare Professionals: Increased confidence and adoption of BRIUMVI due to strong uptake and compelling patient experiences.
• Partners (Neuraxpharm): Continued successful collaboration and expansion of BRIUMVI commercialization outside the U.S.

Next Steps

• Host a conference call on August 4, 2025, at 8:30 AM ET to discuss the company's financial results.
• Commence patient enrollment into the Phase 3 pivotal program for subcutaneous BRIUMVI.
• Continue enrollment into the Phase 3 pivotal program based on the streamlined dosing regimens evaluated in the ENHANCE trial, evaluating a single Day 1 600 mg IV dose of BRIUMVI.
• Continue enrollment of participants into the ongoing clinical trial evaluating BRIUMVI in Myasthenia Gravis (MG).
• Continue enrollment of participants into the Phase 1 clinical trial evaluating azer-cel for the treatment of autoimmune diseases, beginning with progressive forms of MS.
• Present updated data at major medical conferences throughout the year.

Key Dates

Recommendation

The company has demonstrated exceptional commercial execution with BRIUMVI, evidenced by the substantial year-over-year and quarter-over-quarter revenue growth and the upward revision of full-year guidance. The transition to profitability and a strong cash position further de-risk the investment. Pipeline advancements, particularly the subcutaneous formulation and streamlined dosing, indicate a proactive strategy to enhance market competitiveness and patient convenience, which could drive further adoption. While R&D and SG&A expenses are increasing, they are tied to growth initiatives and pipeline development, which are necessary investments for a biopharmaceutical company. The overall trajectory suggests strong operational momentum and future growth potential in a significant market.

Keywords

TG Therapeutics, TGTX, BRIUMVI, ublituximab-xiiy, Multiple Sclerosis, MS, Relapsing MS, Biopharmaceutical, Drug Development, Commercialization, Financial Results, Revenue Guidance, Anti-CD20, Autoimmune Diseases, Azer-cel, Myasthenia Gravis